Your browser is no longer supported. Please, upgrade your browser.
Settings
CLRB Cellectar Biosciences, Inc. daily Stock Chart
CLRB [NASD]
Cellectar Biosciences, Inc.
Index- P/E- EPS (ttm)-1.24 Insider Own3.70% Shs Outstand15.92M Perf Week-12.50%
Market Cap26.75M Forward P/E- EPS next Y-0.87 Insider Trans0.00% Shs Float12.29M Perf Month-5.62%
Income-10.90M PEG- EPS next Q-0.25 Inst Own7.00% Short Float10.41% Perf Quarter13.34%
Sales- P/S- EPS this Y80.60% Inst Trans0.36% Short Ratio4.60 Perf Half Y-20.38%
Book/sh1.14 P/B1.47 EPS next Y5.40% ROA-48.20% Target Price3.10 Perf Year-21.50%
Cash/sh0.70 P/C2.39 EPS next 5Y- ROE-56.20% 52W Range1.12 - 3.07 Perf YTD37.70%
Dividend- P/FCF- EPS past 5Y53.40% ROI- 52W High-45.28% Beta1.03
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low50.00% ATR0.13
Employees15 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)47.35 Volatility8.10% 7.03%
OptionableNo Debt/Eq0.00 EPS Q/Q-126.50% Profit Margin- Rel Volume0.40 Prev Close1.73
ShortableYes LT Debt/Eq0.00 EarningsNov 13 AMC Payout- Avg Volume278.06K Price1.68
Recom1.00 SMA20-4.10% SMA50-0.47% SMA200-6.86% Volume112,554 Change-2.89%
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Oct-17-17 08:30AM  Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors GlobeNewswire
Oct-12-17 11:00AM  Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering GlobeNewswire -6.25%
Oct-10-17 01:30PM  Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market GlobeNewswire
07:30AM  Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates GlobeNewswire
Sep-29-17 08:30AM  Cellectar Biosciences to Present at The MicroCap Conference GlobeNewswire
Sep-27-17 08:30AM  Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131 GlobeNewswire
Sep-21-17 08:30AM  Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates GlobeNewswire
Sep-20-17 08:30AM  Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-18-17 08:30AM  Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer GlobeNewswire
Sep-06-17 08:30AM  Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference GlobeNewswire
Aug-22-17 08:30AM  Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window GlobeNewswire +20.95%
Aug-15-17 03:10PM  Edited Transcript of CLRB earnings conference call or presentation 14-Aug-17 9:00pm GMT Thomson Reuters StreetEvents +5.44%
Aug-14-17 04:45PM  Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance GlobeNewswire
Aug-08-17 08:30AM  Cellectar Biosciences CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients GlobeNewswire +11.39%
Aug-03-17 08:30AM  Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance GlobeNewswire
Aug-01-17 08:30AM  Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors GlobeNewswire
Jun-15-17 07:17AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jun-06-17 08:30AM  Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference GlobeNewswire
May-30-17 08:30AM  Cellectar Biosciences to Present at the LD Micro Invitational Conference GlobeNewswire
May-18-17 08:30AM  Three Abstracts on Dosing Regimens of Cellectars CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings GlobeNewswire
May-12-17 11:37AM  Edited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 04:05PM  Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance GlobeNewswire
May-02-17 08:30AM  Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance GlobeNewswire
Apr-27-17 08:30AM  Cellectars Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies GlobeNewswire -5.89%
Apr-25-17 08:30AM  Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers GlobeNewswire
Apr-21-17 04:15PM  UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer GlobeNewswire
Apr-18-17 08:30AM  Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells GlobeNewswire
Apr-12-17 08:30AM  Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer GlobeNewswire
Apr-10-17 04:05PM  Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors GlobeNewswire
Mar-30-17 04:04PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers GlobeNewswire
Mar-21-17 04:04PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
01:04PM  CELLECTAR BIOSCIENCES, INC. Financials
08:30AM  Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC GlobeNewswire
Mar-16-17 03:57PM  Edited Transcript of CLRB earnings conference call or presentation 15-Mar-17 10:00pm GMT Thomson Reuters StreetEvents -7.00%
08:31AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-15-17 06:00PM  Cellectar Biosciences Inc Earnings Call scheduled for 6:00 pm ET today
04:15PM  Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 GlobeNewswire
09:03AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
Mar-14-17 04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
02:15PM  Cellectar Biosciences Secures Japanese Patent Investopedia
02:15PM  Cellectar Biosciences Secures Japanese Patent at Investopedia
08:30AM  Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences Intellectual Property Portfolio GlobeNewswire
Mar-09-17 05:24PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance GlobeNewswire
Mar-08-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.38%
08:00AM  Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement GlobeNewswire
Mar-06-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.21%
08:30AM  Cellectar Biosciences to Present at 29th Annual Roth Conference GlobeNewswire
Feb-27-17 04:09PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months GlobeNewswire
Feb-22-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.41%
08:30AM  Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma GlobeNewswire
Feb-13-17 03:54PM  Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma
07:00AM  UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-10-17 06:12AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-09-17 08:30AM  Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Accesswire +13.66%
Feb-07-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-03-17 05:01PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Other Events
Jan-31-17 04:08PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform GlobeNewswire
Jan-26-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at NobleCon13 GlobeNewswire
Jan-25-17 11:48AM  Cellectar Biosciences Secures Cancer Drug Patent at Investopedia
Jan-24-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +12.32%
08:30AM  Cellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors GlobeNewswire
Jan-05-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at the 9th Annual Biotech Showcase GlobeNewswire
Dec-21-16 06:59AM  Coverage initiated on Cellectar Biosciences by Ladenburg Thalmann
Dec-20-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs GlobeNewswire
Dec-19-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Other Events -6.20%
Dec-14-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -6.06%
08:30AM  Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types GlobeNewswire
Dec-12-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035 GlobeNewswire
Dec-09-16 04:07PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-06-16 04:08PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology GlobeNewswire
Dec-01-16 04:09PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies GlobeNewswire
Nov-30-16 04:33PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, -5.16%
Nov-29-16 06:40PM  Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option GlobeNewswire
Nov-28-16 04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production GlobeNewswire
Nov-23-16 11:47AM  Cellectar Biosciences (CLRB), Juno Therapeutics (JUNO), Newmont Mining (NEM) and More: What is Going on With These Falling Stocks? at Insider Monkey -31.02%
08:30AM  Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering GlobeNewswire
Nov-17-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:11AM  Movers In Biotech: Cellectar Biosciences Inc (CLRB) And The Medicines Company (MDCO) at Insider Monkey
08:00AM  Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors GlobeNewswire
Nov-16-16 09:00AM  SeeThruEquity Issues Update on Cellectar Biosciences, Inc. (NASDAQ:CLRB) Accesswire +12.76%
Nov-15-16 10:00AM  Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial GlobeNewswire +26.35%
Nov-11-16 07:05PM  Cellectar Biosciences Inc (CLRB) Is Oversold And Ready To Bounce Higher at Insider Monkey +7.34%
01:50PM  UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results GlobeNewswire
Nov-10-16 04:32PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:15PM  Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results GlobeNewswire
04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 04:07PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Host Conference Call on November 11 to Report Third Quarter 2016 Financial Results and Corporate Performance GlobeNewswire
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. In addition, the company is developing CLR 1601-PTX, CLR 1602-PTX, and CLR 1603-PTX product candidates, which are in pre-clinical research for the treatment of chemotherapy. It has strategic collaboration with Onconova Therapeutics, Inc. to develop phospholipid drug conjugates. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEIS JOHNDirectorNov 29Buy1.49333,333496,666631,317Nov 30 06:59 PM